[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100524249":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":21,"locations":27,"responsibleParty":41,"collaborators":44,"id":48,"slug":7,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":49,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":7,"studyType":61,"phases":7,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":30,"whyStopped":7,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Mayo Clinic","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DEVICE","Rectal Artery Embolization","Subjects will undergo planned rectal artery embolization (RAE) in Vascular and Interventional Radiology per standard clinical protocol.",[14,18],{"name":15,"affiliation":16,"role":17},"Scott Thompson, MD, PhD","Mayo Clinic, Vascular and Interventional Radiology","PRINCIPAL_INVESTIGATOR",{"name":19,"affiliation":20,"role":17},"Scott R Kelley, MD","Mayo Clinic, Colon and Rectal Surgery",[22],{"name":23,"role":24,"phone":25,"phoneExt":7,"email":26},"Desirae Howe-Clayton","CONTACT","507-255-0111","Howe.Desirae@mayo.edu",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":7},"Mayo Clinic Minnesota","RECRUITING","Rochester","Minnesota","55905","United States",{"type":36,"coordinates":37},"Point",[38,39],-92.4699,44.02163,{"lat":39,"lon":38},{"type":17,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Scott M. Thompson","Principal Investigator",[45],{"name":46,"class":47},"Terumo Corporation","INDUSTRY","100524249",false,"NCT06106269","Outcomes and Quality of Life Following Rectal Artery Embolization for Bleeding Internal Hemorrhoids","Hemorrhoidal Embolization Trial-1 (HEMBO-1)","HEMBO-1","Inclusion Criteria:\n\n* Grade II or III hemorrhoidal disease as determined by a board-certified colorectal surgeon.\n* Persistent or recurrent symptoms following hygiene and dietary measures or medication.\n* Bleeding predominant ± pain symptoms.\n* Undergoing planned rectal artery embolization (RAE) per standard clinical care.\n* Male or female with age greater than 18 years, with the capacity and willingness to provide a written informed consent.\n* Negative pregnancy test (if applicable).\n\nExclusion Criteria:\n\n* Prior hemorrhoid surgery.\n* Grade IV hemorrhoidal disease.\n* Acute hemorrhoid complications.\n* Chronic anal or perianal fissures.\n* History of colorectal surgery or pelvic radiation.\n* Inflammatory bowel disease.\n* Portal hypertension or mesenteric venous congestion\u002Focclusion.\n* Inferior mesenteric artery (IMA) or internal iliac artery (IIA) stenosis or occlusion.\n* Contraindication to iodinated contrast.\n* Pregnant and\u002For breast-feeding subjects. A negative pregnancy test within 48 hours of the procedure per clinical care.","ALL","18 Years","90 Years",{"count":59,"type":60},20,"ESTIMATED","OBSERVATIONAL","This study will assess how effective and safe rectal artery embolization works to treat symptomatic bleeding predominant internal hemorrhoids.",[64],"Internal Hemorrhoid",[66,67,68],"Bleeding","Anemia","Hemorrhoid","2026-06-15",{"date":71,"type":72},"2026-06-17","ACTUAL",{"date":74,"type":72},"2024-06-07",{"date":76,"type":60},"2026-12",{"name":5,"class":6},1]